Health

Writer Advocates for Earlier Consideration of ECT for Severe Depression

A writer who underwent electroconvulsive therapy for treatment-resistant depression argues that earlier intervention could reduce patient suffering and potential side effects.

Ted Scheinman, a writer who faced years of treatment-resistant depression, recently documented his experience with electroconvulsive therapy (ECT) and suggested that the medical establishment’s current approach of utilizing the procedure only as a last resort may prolong unnecessary suffering.

In 2021, after exhausting various pharmaceutical options—including multiple selective serotonin reuptake inhibitors (SSRIs), tricyclic and tetracyclic antidepressants, and monoamine oxidase inhibitors (MAOIs)—Scheinman underwent ECT. He described a demanding regimen of approximately two dozen sessions, roughly double the typical course of 10 to 12 treatments, to manage a condition that had left him struggling with day-to-day functioning.

Modern psychiatric practice in the United States typically reserves ECT for patients who have failed to show improvement through talk therapy and various medication protocols. Harold Sackeim, a professor of psychiatry at the Medical University of South Carolina and a prominent figure in neuromodulation, noted that the medical field has increasingly narrowed the scope of ECT to only the most treatment-resistant individuals. Historically, however, ECT was often used as a first-line treatment for depression, with pioneers like Lothar Kalinowsky previously suggesting that five or six sessions could be effective.

During his treatment, Scheinman reported side effects, most notably memory loss, which he attributed to the duration of the course. However, he emphasized that the therapy ultimately enabled him to resume professional and personal activities, such as writing and performing music, which had been previously hindered by his illness.

Scheinman and the clinicians he consulted argue that earlier intervention could potentially require fewer treatment sessions, thereby reducing the severity of side effects such as memory loss. Supporting this, recent research suggests that ECT can stimulate neurogenesis and promote the growth of the hippocampus, a brain region often affected by chronic depression.

While acknowledging the historical misuse of ECT and the reality of its side effects, Scheinman’s account advocates for a reevaluation of the “last resort” model. He contends that waiting until a patient is in a state of extreme crisis may delay recovery and necessitate more extensive—and potentially more damaging—treatment courses. He emphasizes that he remains hopeful that future patients suffering from severe depression might be able to access the treatment sooner, potentially sparing them from the prolonged decline he experienced before finally undergoing the procedure.

Evelyn Price

Evelyn Price covers health news, medical research, public health developments, and wellness topics. She aims to present evidence-based information in clear language, helping readers understand important studies, health policies, and advances in medicine.
Back to top button